Eligible patients were randomly allocated to receive one of two treatment sequences ( placebo first followed by ivacaftor @ mg twice daily -LSB- sequence @ -RSB- or ivacaftor @ mg twice daily first followed by placebo -LSB- sequence @ -RSB- ) of @ days ' treatment in each period , with a @-day washout between the two treatment periods .